BCRX Valuation
BioCryst Pharmaceuticals Inc
$
8.310
- Overview
- Forecast
- Valuation
- Earnings
BCRX Relative Valuation
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCRX is overvalued; if below, it's undervalued.
Historical Valuation
BioCryst Pharmaceuticals Inc (BCRX) is now in the Fair zone, suggesting that its current forward PS ratio of 2.78 is considered Fairly compared with the five-year average of -34.01. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 5.45 to 35.12 according to relative valuation methord.
Relative Value
Fair Zone
5.45-35.12
Current Price：8.33
Fair
18.39
PE
1Y
3Y
5Y
Trailing
Forward
19.87
EV/EBITDA
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBITDA of 19.87. The 5-year average EV/EBITDA is -9.49. The thresholds are as follows: Strongly Undervalued below -133.61, Undervalued between -133.61 and -71.55, Fairly Valued between 52.58 and -71.55, Overvalued between 52.58 and 114.64, and Strongly Overvalued above 114.64. The current Forward EV/EBITDA of 19.87 falls within the Historic Trend Line -Fairly Valued range.
17.41
EV/EBIT
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBIT of 17.41. The 5-year average EV/EBIT is 8.67. The thresholds are as follows: Strongly Undervalued below -118.60, Undervalued between -118.60 and -54.96, Fairly Valued between 72.31 and -54.96, Overvalued between 72.31 and 135.94, and Strongly Overvalued above 135.94. The current Forward EV/EBIT of 17.41 falls within the Historic Trend Line -Fairly Valued range.
2.76
PS
BioCryst Pharmaceuticals Inc. (BCRX) has a current PS of 2.76. The 5-year average PS is 7.68. The thresholds are as follows: Strongly Undervalued below -4.68, Undervalued between -4.68 and 1.50, Fairly Valued between 13.86 and 1.50, Overvalued between 13.86 and 20.04, and Strongly Overvalued above 20.04. The current Forward PS of 2.76 falls within the Historic Trend Line -Fairly Valued range.
25.82
P/OCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/OCF of 25.82. The 5-year average P/OCF is -14.41. The thresholds are as follows: Strongly Undervalued below -71.29, Undervalued between -71.29 and -42.85, Fairly Valued between 14.04 and -42.85, Overvalued between 14.04 and 42.48, and Strongly Overvalued above 42.48. The current Forward P/OCF of 25.82 falls within the Overvalued range.
13.17
P/FCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/FCF of 13.17. The 5-year average P/FCF is 0.44. The thresholds are as follows: Strongly Undervalued below -160.20, Undervalued between -160.20 and -79.88, Fairly Valued between 80.76 and -79.88, Overvalued between 80.76 and 161.07, and Strongly Overvalued above 161.07. The current Forward P/FCF of 13.17 falls within the Historic Trend Line -Fairly Valued range.
BioCryst Pharmaceuticals Inc (BCRX) has a current Price-to-Book (P/B) ratio of -4.22. Compared to its 3-year average P/B ratio of -4.40 , the current P/B ratio is approximately -4.05% higher. Relative to its 5-year average P/B ratio of -11.86, the current P/B ratio is about -64.44% higher. BioCryst Pharmaceuticals Inc (BCRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.88%. Compared to its 3-year average FCF yield of -6.59%, the current FCF yield is approximately -113.36% lower. Relative to its 5-year average FCF yield of -7.13% , the current FCF yield is about -112.36% lower.
-4.14
P/B
Median3y
-4.40
Median5y
-11.86
0.89
FCF Yield
Median3y
-6.59
Median5y
-7.13
Competitors Valuation Multiple
The average P/S ratio for BCRX's competitors is 2.67, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of 2.76, which is 3.55% above the industry average. Given its robust revenue growth of 49.41%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BCRX decreased by 4.37% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -26.95 to -46.64.
The secondary factor is the Revenue Growth, contributed 49.41%to the performance.
Overall, the performance of BCRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is BioCryst Pharmaceuticals Inc (BCRX) currently overvalued or undervalued?
BioCryst Pharmaceuticals Inc (BCRX) is now in the Fair zone, suggesting that its current forward PS ratio of 2.78 is considered Fairly compared with the five-year average of -34.01. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 5.45 to 35.12 according to relative valuation methord.
What is BioCryst Pharmaceuticals Inc (BCRX) fair value?
How does BCRX's valuation metrics compare to the industry average?
What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Aug 30 2025?
What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX) as of Aug 30 2025?
What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Aug 30 2025?